MET and cancer: Agents targeting HGF/c-MET, including small molecules such as crizotinib, tivantinib and cabozantinib, as well as the antibodies like rilotumumab and onartuzumab, have demonstrated efficacy in various cancers (Moosavi et al., 2021).